Hepatocellular Carcinoma Clinical Trials in San Antonio, Texas

9 studies are recruiting for hepatocellular carcinoma in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

2. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   10 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

3. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START-San Antonio, San Antonio, Texas

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

4. IDOV-Immune for Advanced Solid Tumors

   This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   5 in total

   Run by

   ViroMissile, Inc.

   See if you can join NCT06910657 on ClinicalTrials.gov

5. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, LLC, San Antonio, Texas

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

6. A Study of ZW251 in Participants With Advanced Solid Tumors

   The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   25 in total

   Run by

   Zymeworks BC Inc.

   See if you can join NCT07164313 on ClinicalTrials.gov

7. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

   The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Health Science Center - San Antonio, San Antonio, Texas

   Locations

   21 in total

   Run by

   Tvardi Therapeutics, Incorporated

   See if you can join NCT05440708 on ClinicalTrials.gov

8. Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

   This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged popul…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UT Health San Antonio, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT06526104 on ClinicalTrials.gov

9. Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

   This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mays Cancer Center, UT Health San Antonio, San Antonio, Texas

   Locations

   3 in total

   Run by

   Anwaar Saeed

   See if you can join NCT06698250 on ClinicalTrials.gov